Laureate Pharma Announces Collaboration With Boehringer Ingelheim
PRINCETON, N.J., February 06, 2007 /PRNewswire/ -- Laureate Pharma, Inc. is pleased to announce a preferred partnership agreement with Boehringer Ingelheim, one of the leading companies in biopharmaceutical development and manufacturing. With this collaboration, Laureate's clients will gain access to Boehringer Ingelheim's comprehensive manufacturing technology platform for biopharmaceutical products produced by mammalian cell culture.
Through this collaboration, Laureate will now offer its clients bioprocessing services that include: creation and development of production cell lines using Boehringer Ingelheim's highly efficient BI HEX expression system; full-service process development and manufacture of early stage clinical supplies at Laureate's cGMP manufacturing facility in Princeton, NJ; and access to large-scale commercial production by Boehringer Ingelheim at its facility in Biberach, Germany. Laureate and Boehringer Ingelheim will harmonize bioprocessing methods to ensure seamless transfer of manufacturing activities from Laureate to Boehringer Ingelheim.
"We are delighted to announce our preferred partnership with Boehringer Ingelheim and view it as a great way to provide our clients with a complete path from clinical-scale production at Laureate to large-scale commercial manufacturing at Boehringer Ingelheim," said Robert J. Broeze, Ph.D., President and Chief Executive Officer of Laureate Pharma. "Working together, Laureate Pharma and Boehringer Ingelheim offer a comprehensive menu of manufacturing solutions in the United States and Europe."
The collaboration with Boehringer Ingelheim complements Laureate's current service offerings with high expression cell line development along with large- scale manufacturing capabilities allowing speed and flexibility, and securing high value for the customer.
"With Laureate Pharma, Boehringer Ingelheim complements its worldwide strategic manufacturing network with a strong partner for process development and clinical material supply. Our process know-how allows state of the art and time to clinic development at Laureate as well as smooth technology transfer to Boehringer Ingelheim's commercial manufacturing," commented Prof. Dr. Dr. h.c. Rolf G. Werner, Senior Vice President, Corporate Division Biopharmaceuticals.
About Laureate Pharma:
Laureate Pharma is a full service biopharmaceutical development and protein production company located in Princeton, NJ. The company is dedicated to supporting the development and commercialization of pharmaceutical products for pharmaceutical and biopharmaceutical companies. Laureate Pharma provides a wide range of specialized product development services from process design and development to full-scale cGMP production, purification and aseptic filling, as well as corresponding testing, validation, analytical services and regulatory support.
Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Mammalian cells are grown in stirred-tank or hollow-fiber bioreactors for production of biopharmaceutical proteins, which are purified by state-of-the-art semi- automated chromatography systems and filled into vials under stringent aseptic conditions. Laureate Pharma, Inc. is a partner company of Safeguard Scientifics, Inc. (http://www.safeguard.com), which builds value in high-growth, revenue stage information technology and life sciences businesses. For more information on Laureate Pharma, Inc. please contact Michael Cavanaugh, Vice President, Sales, Marketing, and Business Development at (609) 919-3400, by email at or visit http://www.laureatepharma.com. email@example.com
About Boehringer Ingelheim:
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since its foundation in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing innovative products of high therapeutic value for human and veterinary medicine. In addition to captive use manufacturing, Boehringer Ingelheim is operating a contract development and industrial customer manufacturing business for Biopharmaceuticals.
Boehringer Ingelheim has developed highly efficient mammalian expression systems for CHO cells, which presently allow productivities of more than 4 g/L in animal component free media. The Boehringer Ingelheim High Expression System (BI HEX) allows the development and production of high-quality products in a time-to-market approach and with economy of scale. For the mammalian cell culture products a total capacity of 180,000 L is available with a scale-up capacity that ranges from 80 to 15,000 L per bioreactor train and downstream processing systems, which are matched to the scale of the production capacity.
For fermentation with E.coli, Boehringer Ingelheim offers high-expression systems with productivities up to 13 g/L in fermentors that range in size from 30 to 6,000 L, giving a total fermentation volume of more than 12,000 L. A further focus is the development and production of products in different yeast systems. With yields of up to 2 g/L, Boehringer Ingelheim has set the standard for manufacturing of plasmid DNA, and today supplies early to late-stage clinical trials for its international clients.
Proprietary media and downstream platform technologies for the production of recombinant proteins, fusion proteins, protein scaffolds and monoclonal antibodies, as well as franchise technologies in liquid and slow release formulation and inhalation devices complement the development and production service of Boehringer Ingelheim.
For more information see:
CONTACT: Michael Cavanaugh, Vice President, Sales, Marketing, and BusinessDevelopment, Laureate Pharma, +1-609-919-3400, or firstname.lastname@example.org
Ticker Symbol: (NYSE:SFE)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: February 2007